| Literature DB >> 29310635 |
Mitsue Sato1,2,3, Masahiro Sugimoto4,5,6, Yuko Yamamoto4, Juri Saruta4,7, Keiichi Tsukinoki4,7.
Abstract
BACKGROUND: Oral functional ability decreases with age, and systemic immunological ability and quality of life can also deteriorate. Continuous moderate whole-body exercise for older people is known to improve oral functional and their immunological abilities. Here, we evaluated the effect of oral exercise as an alternative training method for highly older people who cannot perform whole-body exercises.Entities:
Keywords: Exercise therapy; Immunoglobulin a; Saliva; Salivary gland; “Aged, 80 and over”
Mesh:
Substances:
Year: 2018 PMID: 29310635 PMCID: PMC5759290 DOI: 10.1186/s12903-017-0461-7
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Salivary parameters
| Parameter | n | Baseline | After 3 weeks | After 6 weeks | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average | SD | Average | SD | Average | SD | ||||||||
| Stimulate saliva flow rate (ml/min) | 25 | 0.563 | 0.185 | 0.515 | 0.168 | −1.06 | 0.29 | 0.472 | 0.160 | −2.14 | 0.034 | * | |
| IgA concentration (μg/ml) | 27 | 91.23 | 58.42 | 87.49 | 75.66 | −2.12 | 0.035 | * | 84.2 | 57.83 | −1.39 | 0.17 | |
| IgA secretion rate (μg/min) | 23 | 54.94 | 42.87 | 42.42 | 37.12 | −2.40 | 0.017 | * | 44.05 | 41.5 | −2.13 | 0.035 | * |
IgA and SD indicated immunoglobulin A and standard deviation, respectively
Z-score and P-values were calculated by Wilcoxon matched-pairs signed rank test (both tailed)
Fig. 1Box-whisker plots of stimulated salivary secretion rate, concentration of IgA and its secretion rate. The horizontal bars indicate 10, 25, 50, 75 and 90% of the data, and data <10% and >90% are depicted in the plots. The data at baseline and at 3 and 6 weeks after oral functional exercise are labelled Baseline, W3 and W6. Saliva flow rate (a), IgA concentration (b), and IgA flow rate (c). Wilcoxon matched-pairs signed rank test (two-tailed) was used. *P < 0.05
Fig. 2The clustering results of participants based on the pattern of stimulated saliva flow rate and IgA secretion rate. The quantified values were divided by the averaged value of each sampling point and colored in black and white for relative higher and lower values, respectively, compared with their average. The color bar (at the upper left) indicates the fold change of each quantified values (0.5, 1.0 and 1.5 indicated fold change). Data at a line indicates the values collected at a time point and data at a column indicates the values for each subject. The top three lines and the bottom three lines indicate the rate of salivary secretion and IgA secretion rate data, respectively. Dendrogram (presented in tree form) indicates the similarity of each column, yielded by clustering analysis. Elucidation distance was used for the clustering algorithm, e.g. columns showing similar data patterns were aligned closely. Diseases and the use of medication are represented by solid dots. Abbreviations are presented in Table 2. Prominent clusters are labelled a, b and c
Comparison of participants’ characteristics based on clustering analysis
| Characteristics | Lower cluster (A) | Higher cluster (B + C) | Statistic Value | Ajusted | ||||
|---|---|---|---|---|---|---|---|---|
| ( | ( | |||||||
| Age (years) | 81.9 ± 8.1 | 84.7 ± 7.1 | 0.39 | 0.71 | ||||
| BMI (kg/m2) | 23.4 ± 2.8 | 20.5 ± 3.4 | 0.039 | * | 0.24 | |||
| Sex | Male | 4 | 3 | χ2 (1, n = 23) = 0.35 | 0.55 | 0.84 | ||
| Female | 7 | 9 | ||||||
| Drink milk | habit | 3 | 3 | χ2 (1, n = 23) = 0.015 | 0.90 | 0.94 | ||
| no habit | 8 | 9 | ||||||
| Eat yogurt | habit | 3 | 3 | χ2 (1, n = 23) = 0.015 | 0.90 | 0.94 | ||
| no habit | 8 | 9 | ||||||
| Exercise | habit | 1 | 1 | χ2 (1, | 0.89 | 0.94 | ||
| no habit | 9 | 11 | ||||||
| False teeth | with | 10 | 11 | χ2 (1, n = 23) = 0.041 | 0.95 | 0.95 | ||
| without | 1 | 1 | ||||||
| Number of colds per year | 0 | 1 | 2 | χ2 (2, | 0.59 | 0.84 | ||
| 1 | 3 | 4 | ||||||
| 2 | 1 | 5 | ||||||
| Number of times brush teeth per day | 2 | 1 | 3 | χ2 (2, n = 23) = 2.18 | 0.34 | 0.71 | ||
| 3 | 10 | 8 | ||||||
| 4 | 0 | 1 | ||||||
| Diabetes | with | 1 | 1 | χ2 (1, n = 22) = 0.011 | 0.88 | 0.94 | ||
| (DM) | without | 10 | 8 | |||||
| Hypertension | with | 3 | 5 | χ2 (1, | 0.06 | 0.29 | ||
| (HT) | without | 8 | 4 | |||||
| Parkinson’s disease | with | 0 | 1 | χ2 (1, n = 20) = 0.82 | 0.26 | 0.62 | ||
| (PD) | without | 11 | 8 | |||||
| Heart diseases | with | 2 | 1 | χ2 (1, n = 20) = 0.099 | 0.66 | 0.88 | ||
| (HD) | without | 9 | 8 | |||||
| Hyperthyroidism | with | 0 | 1 | χ2 (1, n = 20) = 0.83 | 0.26 | 0.62 | ||
| (HO) | without | 11 | 8 | |||||
| Cerebrovascular disease | with | 7 | 3 | χ2 (1, n = 20) = 0.92 | 0.18 | 0.62 | ||
| (CD) | without | 4 | 6 | |||||
| Anti-hypertensive agent | use | 6 | 3 | χ2 (1, n = 20) = 0.15 | 0.58 | 0.84 | ||
| (AH) | no use | 5 | 6 | |||||
| Diuretics | use | 0 | 1 | χ2 (1, n = 20) = 0.83 | 0.26 | 0.62 | ||
| (DR) | no use | 11 | 8 | |||||
| Psychotropic drug | use | 2 | 2 | χ2 (1, n = 20) = 0.025 | 0.82 | 0.94 | ||
| (PS) | no use | 9 | 7 | |||||
| Antidepressants | use | 1 | 0 | χ2 (1, n = 20) = 0.69 | 0.35 | 0.71 | ||
| (AD) | no use | 10 | 9 | |||||
| Methyldopa | use | 0 | 1 | χ2 (1, n = 20) = 0.83 | 0.26 | 0.62 | ||
| (ME) | no use | 11 | 8 | |||||
| H2 blocker | use | 1 | 2 | χ2 (1, n = 20) = 0.33 | 0.41 | 0.71 | ||
| (HB) | no use | 10 | 7 | |||||
| Stimulated saliva flow rate (ml/min) | 0.46 ± 0.11 | 0.59 ± 0.085 | 0.0049 | ** | 0.039 | * | ||
| IgA concentration (μg/ml) | 57.7 ± 30.1 | 107 ± 27.8 | 0.0039 | ** | 0.039 | * | ||
| IgA secretion rate (μg/min) | 26.4 ± 13.5 | 63.8 ± 16.2 | 0.00060 | *** | 0.014 | * | ||
No participants had depression or epilepsy, and none used anti-hyperglycemic agents, antihistamine or α1-blocking drugs
Statistic value of χ2 test (two-sided) included degree of freedom, sample, size and P-values
Z-score and P-values were calculated by Wilcoxon rank-sum test (both tailed)
Comparison of participant characteristics based on diseases present and medication use
| Characteristics | Salivary flow (ml/min) | Ajusted | IgA concentration (μg/ml) | Ajusted | IgA secretion rate (μg/min) | Ajusted | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| without/no use | with/use | without/no use | with/use | without/no use | with/use | ||||||||||||||||||||||
| Average ± S.D. | n | Average ± S.D. | n | Average ± S.D. | n | Average ± S.D. | n | Average ± S.D. | n | Average ± S.D. | n | ||||||||||||||||
| Diabetes | 0.54 ± 0.11 | 21 | 0.56 ± 0.23 | 2 | 0.273 | 0.74 | 0.81 | 87.0 ± 44.6 | 21 | 122 ± 14.7 | 2 | 1.36 | 0.16 | 0.52 | 50.8 ± 30.9 | 21 | 66.8 ± 19.6 | 2 | 0.927 | 0.33 | 0.52 | ||||||
| Hypertension | 0.51 ± 0.13 | 14 | 0.58 ± 0.084 | 9 | 1.23 | 0.21 | 0.50 | 81.8 ± 42.7 | 14 | 103 ± 45.0 | 9 | 1.10 | 0.26 | 0.52 | 46.0 ± 29.7 | 14 | 62.0 ± 29.7 | 9 | 1.291 | 0.19 | 0.52 | ||||||
| Parkinson’s disease | 0.52 ± 0.11 | 21 | 0.69 ± 0.03 | 2 | 2.02 | 0.04 | * | 0.24 | 89.1 ± 44.6 | 22 | 112 | 1 | 0.678 | 0.45 | 0.54 | 50.9 ± 30.1 | 22 | 80.8 | 1 | 0.98 | 0.29 | 0.54 | |||||
| Heart diseases | 0.55 ± 0.11 | 19 | 0.49 ± 0.03 | 4 | 0.771 | 0.42 | 0.55 | 87.5 ± 37.5 | 19 | 102 ± 73.8 | 4 | 0.284 | 0.11 | 0.52 | 51.7 ± 26.8 | 19 | 54.9 ± 48.2 | 4 | 0.041 | 0.94 | 0.52 | ||||||
| Hyperthyroidism | 0.54 ± 0.12 | 22 | 0.45 | 1 | 0.678 | 0.45 | 0.55 | 89.2 ± 44.7 | 22 | 111 | 1 | 0.528 | 0.55 | 0.60 | 52.3 ± 30.8 | 22 | 50.4 | 1 | 0 | 1.00 | 0.60 | ||||||
| Cerebrovascular disease | 0.56 ± 0.11 | 12 | 0.51 ± 0.13 | 11 | 0.954 | 0.32 | 0.55 | 101 ± 42.9 | 11 | 80.2 ± 44.2 | 12 | 1.26 | 0.20 | 0.52 | 56.7 ± 28.8 | 11 | 48.1 ± 31.9 | 12 | 0.769 | 0.42 | 0.52 | ||||||
| Antihypertensive agent | 0.54 ± 0.14 | 8 | 0.54 ± 0.11 | 15 | 0.161 | 0.85 | 0.85 | 63.1 ± 27.5 | 8 | 105 ± 44.8 | 15 | 2.03 | 0.04 | * | 0.48 | 40.0 ± 24.7 | 8 | 58.7 ± 31.4 | 15 | 1.323 | 0.18 | 0.48 | |||||
| Diuretics | 0.53 ± 0.13 | 20 | 0.63 ± 0.053 | 3 | 1.90 | 0.06 | 0.24 | 86.5 ± 39.9 | 21 | 127 ± 86.2 | 2 | 0.709 | 0.45 | 0.54 | 49.6 ± 27.2 | 21 | 79.6 ± 59.6 | 2 | 0.818 | 0.38 | 0.54 | ||||||
| Psychotropic drugs | 0.55 ± 0.12 | 19 | 0.50 ± 0.12 | 4 | 0.689 | 0.46 | 0.55 | 93.6 ± 44.0 | 19 | 73.7 ± 45.5 | 4 | 0.771 | 0.42 | 0.54 | 54.6 ± 30.0 | 19 | 40.7 ± 31.9 | 4 | 0.771 | 0.42 | 0.54 | ||||||
| Antidepressants | 0.55 ± 0.11 | 22 | 0.4 | 1 | 0.957 | 0.34 | 0.55 | 88.2 ± 43.9 | 22 | 133 | 1 | 0.258 | 0.23 | 0.52 | 52.2 ± 30.8 | 22 | 53 | 1 | 0.226 | 0.76 | 0.52 | ||||||
| Methyldopa | 0.52 ± 0.11 | 21 | 0.69 ± 0.034 | 2 | 2.02 | 0.04 | * | 0.24 | 89.1 ± 44.6 | 22 | 112 | 1 | 0.678 | 0.45 | 0.54 | 50.9 ± 30.1 | 22 | 80.8 | 1 | 0.98 | 0.29 | 0.54 | |||||
| H2 blocker | 0.54 ± 0.12 | 20 | 0.52 ± 0.12 | 3 | 0.320 | 0.13 | 0.39 | 91.6 ± 45.0 | 20 | 80.3 ± 42.2 | 3 | 0.320 | 0.72 | 0.72 | 53.6 ± 31.0 | 20 | 43.1 ± 25.9 | 3 | 0.411 | 0.65 | 0.72 | ||||||
Note: Participants showing high value ≥ average + 3 × SD were eliminated as outliers (one participant was eliminated for each comparison)
Z-score and P-values were calculated by Wilcoxon rank-sum test (both tailed)
Fig. 3The change in salivary parameters for each group showing a lower stimulated saliva secretion rate and IgA secretion rate (cluster A in Fig. 2) and higher values (clusters B + C in Fig. 2). Salivary secretion flow rate (a) and (b), concentration of IgA (c) and (d), and the secretion rate of IgA (e) and (f). Panels a, c and e present the data in cluster A (n = 11) and panels b, d and f present the data in the clusters B + C (n = 12). Only the data without any missing value was used. Wilcoxon matched-pairs signed rank test (two-tailed) was used. *P < 0.05